After three years, Roche gains full ownership of Foundation Medicine for $2.4bn
Executive Summary
Roche acquired the remaining 43% stake of publicly traded tumor genomic profiling company Foundation Medicine Inc. (FMI) that it didn’t already own for $2.4bn on a fully diluted basis (total company value of $5.3bn on a fully diluted basis). Roche paid $137 in cash per share, a 34% premium.
Deal Industry
- In Vitro Diagnostics
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Partial Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice